Please assess the completion status of the following clinical trial:

Trial Title: Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infection documented by confirmed positive HIV-1 antibody test and/or positive polymerase chain reaction for HIV-1 ribonucleic acid (RNA).~* Adult patients (over 18 years of age).~* Current HAART regimen containing zidovudine + lamivudine at usual doses for at least 6 months.~* Viral load \< 50 copies/mL on the last two consecutive determinations, under zidovudine + lamivudine containing HAART regimen.~* For women of childbearing potential, negative urine pregnancy test at screening visit.~* Agreement to take part in the study and sign the informed consent.~* Patients on lipid lowering treatment were allowed to participate in the study only if the lipid-lowering treatment (either statins or fibrates) was stable for at least 8 weeks prior to screening and it was not expected to change during the first 3 months of the study.~Exclusion Criteria:~* Patients on current FTC or TDF therapy.~* Patients with previous history of virological failure on an FTC or TDF-containing regimen.~* Patients receiving a non-registered antiretroviral drug.~* Patients receiving a triple-nucleoside antiretroviral combination.~* Hypersensitivity to one of the components of the dosage forms of TDF or FTC, or previous history of intolerance to one of those drugs.~* Known history of drug abuse or chronic alcohol consumption~* Women who were pregnant or breast feeding, or female of childbearing potential who did not use an adequate method of contraception according to the investigator's judgment.~* Active opportunistic infection or documented infection within the previous 4 weeks.~* Documented active malignant disease (excluding Kaposi sarcoma limited to the skin).~* Renal disease with creatinine clearance \< 50 mL/min.~* Concomitant use of nephrotoxic or immuno-suppressive drugs which could not be stopped without affecting the safety of the patient.~* Receiving on-going therapy with systemic corticosteroids, Interleukin-2 or chemotherapy.~* Patients who were not to be included in the study according to the investigator's criterion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Truvada (Type: EXPERIMENTAL): Truvada + NNRTI or PI.
- Zidovudine/lamivudine (Type: ACTIVE_COMPARATOR): Zidovudine/lamivudine + NNRTI or PI.

Based on this trial design, predict the completion outcome and termination type (if applicable).